Drug Approval | June 11, 2021
CSIR join hands with SUVEN Pharmaceuticals
The agreements between the parties involve a total fee of Rs. 8 lakh plus taxes for the grant of the licenses on a non-exclusive basis to SPL
The agreements between the parties involve a total fee of Rs. 8 lakh plus taxes for the grant of the licenses on a non-exclusive basis to SPL
The company's operating revenue for Q4 FY21 was Rs. 330.2 crore
This investment is being made to set up a high speed 400 vials a minute injectable fill line with isolator technology
The GMP certificate is valid for three years until April 2024.
With the surge of infections in India in the recent days AmphoTLC will address the country's acute liposomal amphotericin B shortage
Availability of drugs is being monitored by implementing a three-pronged strategy of supply chain management, demand side management, and affordability.
The outlook for the US business remains good as respiratory pipeline (gAbraxane, gAdvair, gDulera) adds medium-term growth visibility.
The agreement will help ensure wider reach and access to patients in India
The rating withdrawal is based on the company’s request and in line with CRISIL Rating’s policy on withdrawal of ratings.
Baricitinib was issued a restricted emergency use approval by the Central Drugs Standard Control Organization (CDSCO)
Subscribe To Our Newsletter & Stay Updated
